Package Leaflet: Information for the User

Similar documents
PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

Prothrombinex -HT Human prothrombin complex, freeze-dried.

Package leaflet: Information for the user. RIXUBIS 500 IU powder and solvent for solution for injection

What Biostate is used for

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

2. What do you need to know before you use Octanate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF) complex, powder for injection. are essential for normal blood clotting.

IMPORTANT: PLEASE READ

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Package leaflet: Information for the user

Package leaflet: Information for the user

IMPORTANT: PLEASE READ

CSL Behring. Beriplex P/N 250, 500 and 1000 IU Powder and solvent for solution for injection Human prothrombin complex

How Berinert works. Before you are given. Berinert. When you must not have it

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

Package leaflet: Information for the user. BeneFIX 250 IU powder and solvent for solution for injection

Before you use NovoThirteen. When NovoThirteen should not be used

Instructional Guide RECONSTITUTION OF IDELVION USING THE MIX2VIAL TRANSFER SET

Package leaflet: Information for the patient. Ruconest 2100 U powder and solvent for solution for injection Conestat alfa

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon

Package leaflet: Information for the user

1. What Voncento is and what it is used for

Package leaflet: Information for the user. Human alpha 1 -proteinase inhibitor

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

4. Possible side effects. treatment. United Kingdom Yellow Card Scheme Website: 5. How to store Nuwiq

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICATION PATIENT MEDICATION INFORMATION. KOVALTRY Antihemophilic Factor (Recombinant)

EVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Contraindication: CinnoVex is contraindicated in patients with a history of hypersensitivity to interferon beta, or

Package leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin

JvD/PL/ PACKAGE LEAFLET

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Package leaflet: Information for the user

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11

Package leaflet: Information for the user

Octocog alfa (rch) [Recombinant Antihaemophilic FVIII, Plasma / Albumin Free Method (rahf-pfm)] injection

Human Normal Immunoglobulin 20% (20 g per 100 ml), solution for subcutaneous administration.

INFORMATION FOR THE CONSUMER

Package leaflet: Information for the user

CONSUMER MEDICINE INFORMATION LEAFLET

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the user

Package leaflet: Information for the user

ADVATE Octocog alfa (rch) [Recombinant Antihaemophilic FVIII, Plasma / Albumin Free Method (rahf-pfm)] injection

PART III: CONSUMER INFORMATION

ALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein INSTRUCTIONS FOR USE Do not Do not YOUR KIT CONTAINS:

Package leaflet: Information for the user

Package leaflet: Information for the patient. Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

Baxter, ADVATE Antihemophilic Factor (Recombinant)

Dorzolamide 20 mg/ml Eye Drops, Solution

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

1. What Miacalcic is and what it is used for

Package leaflet: Information for the patient. Revestive 5 mg powder and solvent for solution for injection Teduglutide

PACKAGE LEAFLET: INFORMATION FOR THE USER

1. What Octostim Nasal Spray is and what it is used for

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

PACKAGE LEAFLET: INFORMATION FOR THE USER. Bricanyl Turbohaler 0.5 mg/dose terbutaline sulphate

Package leaflet: Information for the patient. Revestive 1.25 mg powder and solvent for solution for injection Teduglutide For children and adolescents

Pfizer, BeneFIX R2 Recombinant Factor IX

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

Package Leaflet: Information for the user

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

Package leaflet: Information for the user. Bricanyl Respules 2.5 mg/ml Nebuliser Solution terbutaline sulfate

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for

Package leaflet: Information for the user. Colecalciferol 3000 IU/ml Oral Solution (colecalciferol)

COMPANY CORE DATA SHEET CCDS (EDS/CORE/ENGLISH)

Package leaflet: Information for the user. Pharmalgen Bee Venom Pharmalgen Wasp Venom. 100μg/ml. powder and solvent for solution for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

FUZEON enfuviride WHAT IS IN THIS LEAFLET BEFORE YOU USE FUZEON WHAT FUZEON IS USED FOR. When you must not use it. Use in children

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

PACKAGE LEAFLET: INFORMATION FOR THE USER Rhinocort Aqua, 64 micrograms, Nasal Spray Budesonide

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. Teduglutide for injection

1 What Engerix B is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)

1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user

Ventolin Injection 500 micrograms/ml salbutamol sulfate

Package leaflet: Information for the user. Cuvitru 200 mg/ml solution for subcutaneous injection Human normal immunoglobulin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the user. Bricanyl Turbohaler 0.5 mg/dose terbutaline sulfate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

Pilocarpine 2% w/v Eye Drops, solution. Pilocarpine 4% w/v Eye Drops, solution. Pilocarpine Hydrochloride

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

Package leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection

Transcription:

Package Leaflet: Information for the User REPLENINE -VF 250 IU, 500 IU, 1000 IU POWDER FOR SOLUTION FOR INJECTION HIGH PURITY FACTOR IX FJL14 Please read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor. This medicine has been prescribed for you personally. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. In this leaflet: 1. What Replenine-VF is and what it is used for 2. Before you use Replenine-VF 3. How to use Replenine-VF 4. Possible side effects 5. How to store Replenine-VF 6. Further information 1. WHAT REPLENINE-VF IS AND WHAT IT IS USED FOR Replenine-VF is a high purity factor IX from human blood plasma obtained from screened donors. It is a white sterile powder, supplied with sterile water (Sterilised Water for Injections). Replenine-VF is given by injection into a vein (intravenously) and is used to prevent and treat bleeding in patients with haemophilia B (an inherited shortage of factor IX in the blood). Your doctor will explain further why this medicine has been given to you. 2. BEFORE YOU USE REPLENINE-VF DO NOT USE this medicine if you: are allergic (hypersensitive) to factor IX or to any of the other ingredients (See Section 6 Further information ). Take special care with Replenine-VF if you: suddenly have unusual bruising and feeling very unwell, which may need specialist medical attention have heart or liver disease, which may need specialist medical attention have a risk of blood clotting have had surgery have a high level of antibodies to factor IX (Your doctor may give you an alternative treatment. He/she will check the level of factor IX and antibodies in your blood before and after treatment, especially for your first injections). When injecting, take special care to keep all needles sterile. If you develop an allergic reaction (see Section 4 Possible side effects for a list of these) stop the treatment and tell your doctor immediately. Your doctor will advise you about any vaccinations you may need as a routine precaution when using a blood plasma product. Your doctor will be extremely careful about using Replenine-VF in new-born infants. Taking other medicines Please tell your doctor if you are taking, or have recently taken, any other medicines, including those obtained without a prescription. These injections must not be mixed with other medicinal products. Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are breast-feeding, tell your doctor. Your doctor will tell you if this product is necessary for you to take at this time.

Driving and using machines There are no known effects of this product on your ability to drive or operate machinery. Please note When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infection. The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus and for the non-enveloped hepatitis A and parvovirus B19 viruses. It is strongly recommended that every time you recieve a dose of Replenine-VF the name and batch number of the product are recorded in order to maintain a record of the batches used. 3. HOW TO USE REPLENINE-VF Always use this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. Adults Replenine-VF should be administered directly into a vein. Use only the recommended injection equipment. Your doctor will explain how much you should use. The dose, especially the first dose, should be given slowly (approximately 3 ml per minute). After reconstitution, the injection should be completed within one hour and the solution must not be stored. If further treatment is needed, doses may be repeated at intervals of 8 to 24 hours, as required. Your doctor will advise you if this is necessary. The table gives the approximate doses of factor IX which are needed to stop bleeding in various conditions: Initial dose of Replenine-VF Condition (IU/kg body weight) Minor spontaneous bleeding in joints and muscles. 17 to 34 Severe bleeding in joints and muscles, bruising, 25 to 51 minor surgery, e.g. tooth extraction, cartilage repair. Life-threatening bleeding, major surgery.* 51 to 85 Table 1- factor IX dosing instructions * In major surgery Replenine-VF may be given either as individual injections or by continuous infusion over several days (see also section: How much is given before, during and after major surgery?). Children Your doctor will recommend the appropriate dose for young children. Generally the calculation of doses for children should follow that for adults. When to inject Replenine-VF The medicine should be injected when the first sign of bleeding occurs. The injection should be repeated as necessary to stop the bleeding. Each individual bleed should be judged on its own severity. Replenine-VF can also be injected as part of treatment to prevent bleeding starting. If you are using this product for the first time, your doctor will supervise you. Dissolving your medicine before use Vial of Replenine-VF Quantity of Water supplied Quantity of Water for Half Volume 250 IU 5 ml 2.5 ml 500 IU 10 ml 5 ml 1000 IU 20 ml 10 ml Table 2 - details of sterile water quantities

1. Replenine-VF must only be dissolved in the sterile water provided with the product. 2. Before you remove the flip-off top, make sure that the vial of Replenine-VF and the container of water supplied with it are both at room temperature (between 20 C and 30 C). 3. Sterile water for use with Replenine-VF is provided in a glass vial with a stopper. 4. Replenine-VF is supplied with the amount of sterile water as shown on the table. 5. Your doctor will tell you if you can dissolve Replenine-VF in half the normal volume of sterile water. How to Dissolve Replenine-VF You can dissolve your product in two ways using the Transfer Device called Mix2Vial TM : (A) Dissolving in Full Volume or (B) Dissolving with Half Volume A) Dissolving in Full Volume The Mix2Vial TM Transfer Device is provided with your product for needle-free, easy and safe use. Step 1 Remove the cap from the product vial and clean the top of the stopper with an alcohol swab. Repeat this step with the sterile water vial. Peel back the top of the Transfer Device package but leave the device in the package. Step 2 Place the blue end of the Transfer Device on the water vial and push straight down until the spike penetrates the rubber stopper and snaps into place. Remove the plastic outer packaging from the Transfer Device and discard it, taking care not to touch the exposed end of the device. Step 4 The sterile water will be pulled into the product vial by the vacuum contained within it. Gently swirl the vial to make sure the product is thoroughly mixed. Do not shake the vial. A clear or slightly pearl-like solution should be obtained, usually in about 2 to 21/2 minutes (5 minutes maximum). Step 5 Separate the empty water vial and blue part from the clear part by unscrewing anti-clockwise. Draw air into the syringe by pulling the plunger to the required volume of water added. Connect the syringe to the white filter. Push the air in the syringe into the vial. Step 3 Turn the water vial upside down with the device still attached. Place the clear end of the Transfer Device on the product vial and push straight down until the spike penetrates the rubber stopper and snaps into place. Step 6 Immediately invert the vial of solution which will be drawn into the syringe. Disconnect the filled syringe from the device. The product is now ready for administration. Follow the normal safety practices for administration. Note: If you have to use more than one vial to make up your required dose, repeat Steps 1 to 6 withdrawing the solution in the vial into the same syringe. The Transfer Device supplied with your product is sterile and cannot be used more than once. When the reconstitution process is complete dispose of in your sharps box.

B) Dissolving with Half Volume To use the Transfer Device when dissolving Replenine-VF in half volumes, it is first necessary to remove and discard half the volume of water from the vial of sterile water. Remove the flip-off cover from the vial of sterile water and clean the top of the stopper with an alcohol swab. Pierce the stopper of the vial of sterile water with a needle and syringe and draw up half the volume of sterile water. Check that the correct amount is withdrawn. The needle and syringe can now be safely disposed of (in your sharps box ). The remaining sterile water in the vial will be used for reconstitution (half the original volume). See Table 2 for quantities of water. To complete the dissolving process follow steps 1-6 in Section A above. The product is then ready for administration. Do not use this medicine if: the water is not pulled into the product vial with either method of reconstitution (this indicates a loss of vacuum in the vial, so the product must not be used). the dissolved product and Sterilised Water for Injections form a gel or a clot (if this happens, please tell Bio Products Laboratory, reporting the batch number printed on the vial). Do not use solutions which are cloudy or have bits in them. Administration User Kit This additional carton can be provided upon request from Bio Products Laboratory, which will include: Alcohol swabs: one is used to clean the vial stoppers after flipping off the caps. The other should be used to disinfect your skin at the injection site. Winged Infusion set: a butterfly No. 23 needle for administration of the product. 20 ml syringe: the dissolved solution is withdrawn into the syringe. This size of syringe is provided to enable more than one vial to be administered using one syringe. Plaster: Injecting the Medicine to stick on the injection site after administration. After the medicine is dissolved: To inject the medicine, attach a suitable needle to the syringe. The dose, especially your first dose, should be given slowly (no more than 3 ml per minute) into your vein. Remember: the solution must not be stored after reconstitution. you must finish injecting the dose into a vein within one hour of dissolving the medicine. the solution must not be added to any other fluids, blood or any other medicine. you should only use the sterile water supplied to make up the solution, never inject the water on its own, without first dissolving the powder in it. How much is given before, during and after major surgery? (See also the Table 1 on Page 2) Before: Major surgery should only be performed when levels of factor IX and factor IX inhibitors (antibodies) in your blood can be tested. If antibodies are not present, a dose is given before the operation to increase the level in your blood to between 80 and 100 IU/dL, usually about 65-85 IU per kg of body weight. After: During the first few days after the operation, the plasma factor IX concentration will be checked at regular periods. A dose of Replenine-VF (factor IX) is usually given every 8 to 24 hours, as needed. After the first few days, the number of doses may be reduced. Treatment is usually continued for 7 days or longer, depending on the type of operation.

If the factor IX concentration does not reach the expected level (this will be tested by your doctor), or if it decreases faster than expected (within 12 hours), an inhibitor of factor IX may be present which stops it from working properly. Your doctor will arrange for the appropriate laboratory tests to see if there is such an inhibitor present. If you use more Replenine-VF than you should If you think you may be using too much, stop the injection and tell your doctor. If you know you have used too much, tell your doctor as soon as possible. If you forget to use Replenine-VF Do not use a double dose to make up for a forgotten dose. If you stop using Replenine-VF Always consult your doctor before deciding to stop your treatment. 4. POSSIBLE SIDE EFFECTS As with all medicines, Replenine-VF may cause side effects, although not everybody gets them. Hypersensitivity or allergic reactions have been observed infrequently in patients treated with factor IX containing products. If you get any of the following symptoms, stop the infusion and tell your doctor immediately: swelling around the face and throat nettle-rash (urticaria) restlessness burning and stinging at the infusion site hives rapid heart beat chills low blood pressure tightness of the chest or wheezing flushing lethargy tingling nausea or vomiting Kidney problems (such as nephrotic syndrome) have been reported in some haemophilia B patients who have inhibitors (antibodies) to factor IX and a history of allergic reaction to factor IX containing products. Inhibitors (antibodies) may develop to factor IX during treatment. This could mean that the treatment does not work properly. If bleeding does not stop after an injection, then speak to your doctor. On rare occasions, fever has been observed (in fewer than 1 in 1,000 people). The use of low purity factor IX products has been associated with heart attack, thrombosis and blood coagulation. The use of high purity factor IX, such as Replenine-VF, is rarely associated with such side effects. In clinical trials with Replenine-VF, the following side effects have been reported in fewer than 1 in 10 people. Reaction at the injection site, e.g. irritation, inflammation. Headache. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. 5. HOW TO STORE REPLENINE-VF Keep out of the reach and sight of children. You should store the powder in its container and carton, in the dark in the refrigerator. Do not freeze. Short periods of storage at room temperature, in the dark, will not damage the product. The vial of sterilised water that comes with the medicine should also be stored in the refrigerator. Do not freeze. Do not use the medicine or the sterilised water after the expiry date, which is stated as EXPIRY on the containers. The expiry date refers to the last day of that month. Do not use the sterilised water if any small bits can be seen in it. Once reconstituted, Replenine-VF must be used within one hour. Disposal After injection of the correct dose, dispose of any solution that remains, along with used syringes, needles and containers. Ask your doctor for a special container ( sharps box ) for this purpose and take it back to the doctor or pharmacist when full. Medicines should not be disposed of via wastewater or household waste.

6. FURTHER INFORMATION What Replenine-VF contains The active substance is human coagulation factor IX. The other ingredients are: protein, glycine, lysine, sodium, citrate, phosphate and chloride. What Replenine-VF looks like and the contents of the pack Replenine-VF is a white, crumbly, sterile powder and is packed in quantities of 250 International Units (IU), 500 IU or 1000 IU in glass vials. These vials are closed with a synthetic rubber stopper under vacuum, held on by a tamper-evident cap. Replenine-VF should only be reconstituted with Sterilised Water for Injections which is supplied with Replenine-VF in clear glass bottles. Provided with the product is a Transfer Device called Mix2Vial TM to enable needle-free, easy and safe reconstitution. An Administration User Kit can be provided upon request which contains: a sterile 20 ml plastic syringe, a single winged infusion set (butterfly needle), alcohol swabs and a sterile plastic dressing. Marketing Authorisation Holder and manufacturer Bio Products Laboratory Limited, Dagger Lane, Elstree, Herts. WD6 3BX, United Kingdom Marketing Authorisation Number PL 08801/0028 This leaflet was last approved in November 2012 For further information or if you have any questions about the use of this product, please contact BPL via the Marketing Department at the address above or through info@bpl.co.uk Bio Products Laboratory Limited, Dagger Lane, Elstree, Herts. WD6 3BX, U.K. Tel: +44 (0)20 8957 2200 FJL14